|
Mar 16
|
Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Mar 15
|
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
|
|
Mar 15
|
Chipotle upgraded, Charter initiated: Wall Street’s top analyst calls
|
|
Mar 15
|
Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler
|
|
Mar 14
|
Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Strategic Focus and Financial ...
|
|
Mar 14
|
Sutro Biopharma Falls as Company Cuts Workforce, Shifts Focus to ADCs
|
|
Mar 14
|
Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’
|
|
Mar 13
|
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 13
|
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
|
|
Mar 13
|
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
|
|
Mar 11
|
Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates
|
|
May 31
|
Shareholders Will Likely Find Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Compensation Acceptable
|
|
May 13
|
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
|
|
May 13
|
Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for
|
|
May 13
|
The past three years for Sutro Biopharma (NASDAQ:STRO) investors has not been profitable
|
|
May 1
|
AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?
|
|
Apr 30
|
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial
|
|
Apr 2
|
Sutro Biopharma, Inc. (NASDAQ:STRO) Analysts Just Cut Their EPS Forecasts Substantially
|
|
Apr 2
|
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
|
|
Mar 27
|
Sutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances
|